Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Barrett Esophagus 15Esophageal Neoplasms 10Colorectal Neoplasms 10Rectal Neoplasms 7Adenocarcinoma Of Esophagus 7Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Gastroesophageal Reflux 4Polyps 3Pathologic Complete Response 3Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Carcinoma 3Precancerous Conditions 2Hyperplasia 2Fistula 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenomatous Polyposis Coli 2Adenocarcinoma 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Signs and Symptoms 1Sarcoma 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22Thiotepa 20Sirolimus 20Azacitidine 20venetoclax 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡